Posted by 
Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body’s cells and tissues, plays a critical role in the immune system’s defence against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.
TIMP-1 protein is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise and destroy cancer cells. The protein enhances antitumor immunity through self-stimulation and by activating surrounding immune cells. As a result, increasing TIMP-1 expression or targeting its negative regulators in tumours with deficient immune responses could potentially improve the effectiveness of current cancer immunotherapies.
“For patients deficient in TIMP-1 expression, our discovery helps create rational therapeutic innovations,” says Carlos Rogerio Figueiredo, Docent and InFLAMES researcher at the University of Turku.
According to Figueiredo, the new findings are also relevant for fighting infections by viruses and bacteria, as the process is part of a universal mechanism that fights microorganisms and cancer in a similar fashion.
The study used samples from the Finnish Auria Biobank for clinical-oriented discoveries, which were further validated with the latest biochemical and immunological tools to propose a new molecular view of how the body fights cancer. Figueiredo thanks the patients as well as Oncologist Maria Sundvall and Pathologist Eva-Maria Birkman from Turku University Hospital for their significant contributions to this project.
“The published research shows how the reverse translational method works in practice. Traditional translational research typically starts with basic laboratory discoveries, which are later tested on patients in clinical trials. The reverse translational approach, on the other hand, starts with real-world data from patient samples to guide focused laboratory studies, thereby enhancing the likelihood of success when applied to patients,” explains Figueiredo.
Figueiredo heads the Medical Immuno-Oncology Research Group (MIORG) at the Faculty of Medicine at the University of Turku, which is affiliated with the Turku Bioscience Centre and supported by the Research Council of Finland, InFLAMES Flagship, the Sigrid Juselius Foundation, and the Jane and Aatos Erkko Foundation.
The findings of the study were published in the journal Genes & Immunity, which is part of the Nature Portfolio series.
InFLAMES Flagship is a joint initiative of University of Turku and Åbo Akademi University, Finland. The goal of the Flagship is to integrate the immunological and immunology-related research activities to develop and exploit new diagnostic and therapeutic tools for personalised medicine. InFLAMES is part of Research Council of Finland’s Flagship Programme.